Cellectis SA Company Profile (NASDAQ:CLLS)

About Cellectis SA (NASDAQ:CLLS)

Cellectis SA logoCellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. The Company also offers rational inverse genetics and targeting recombination tools. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CLLS
  • CUSIP: N/A
  • Web: www.cellectis.com
Capitalization:
  • Market Cap: $856.87 million
  • Outstanding Shares: 35,335,000
Average Prices:
  • 50 Day Moving Avg: $23.78
  • 200 Day Moving Avg: $20.63
  • 52 Week Range: $16.09 - $34.23
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.63
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $55.82 million
  • Price / Sales: 15.35
  • Book Value: $7.78 per share
  • Price / Book: 3.12
Profitability:
  • EBIDTA: ($62,130,000.00)
  • Net Margins: -59.01%
  • Return on Equity: -15.67%
  • Return on Assets: -12.38%
Debt:
  • Current Ratio: 5.08%
  • Quick Ratio: 5.08%
Misc:
  • Average Volume: 115,227 shs.
  • Beta: 2.22
  • Short Ratio: 6.49
 

Frequently Asked Questions for Cellectis SA (NASDAQ:CLLS)

What is Cellectis SA's stock symbol?

Cellectis SA trades on the NASDAQ under the ticker symbol "CLLS."

How were Cellectis SA's earnings last quarter?

Cellectis SA (NASDAQ:CLLS) released its earnings results on Monday, November, 16th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.43) by $0.03. The firm earned $11.10 million during the quarter, compared to analyst estimates of $1.23 million. Cellectis SA had a negative net margin of 59.01% and a negative return on equity of 15.67%. View Cellectis SA's Earnings History.

Where is Cellectis SA's stock going? Where will Cellectis SA's stock price be in 2017?

6 brokers have issued 1 year price objectives for Cellectis SA's shares. Their forecasts range from $40.00 to $49.00. On average, they anticipate Cellectis SA's stock price to reach $44.25 in the next twelve months. View Analyst Ratings for Cellectis SA.

What are analysts saying about Cellectis SA stock?

Here are some recent quotes from research analysts about Cellectis SA stock:

  • 1. According to Zacks Investment Research, "Cellectis SA is a gene-editing company. The company focused on developing immunotherapies based on gene edited engineered CAR-T cells. Cellectis SA is based in Paris, France. " (4/4/2017)
  • 2. Instinet analysts commented, "Cellectis is a leader in gene-editing and autologous CAR-T therapy. Recently presented clinical data for UCART19 established proof-of-concept (POC) for a safe off-the-shelf CAR-T (UCART) therapy. We believe that this POC enables rapid development of novel UCART therapeutics and that next-generation treatment protocols and gene-edits entering clinical testing in 2017 will allow for next UCART therapies to enter trials in rapid succession, driving upside in the shares over the next 12 months. We also view the shares as attractively priced, given that CLLS, a clinical-stage biotech, trades at a discount to preclinical gene-editing and clinical-stage CAR-T peers." (3/1/2017)

Are investors shorting Cellectis SA?

Cellectis SA saw a drop in short interest during the month of March. As of March 31st, there was short interest totalling 741,764 shares, a drop of 13.3% from the March 15th total of 855,352 shares. Based on an average daily volume of 110,288 shares, the short-interest ratio is presently 6.7 days.

Who are some of Cellectis SA's key competitors?

When did Cellectis SA IPO?

(CLLS) raised $129 million in an initial public offering (IPO) on Wednesday, March 25th 2015. The company issued 3,500,000 shares at a price of $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray served as the underwriters for the IPO and Oppenheimer was co-manager.

Who owns Cellectis SA stock?

Cellectis SA's stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (9.99%), Tekla Capital Management LLC (0.88%), Lazard Asset Management LLC (0.85%), Sphera Funds Management LTD. (0.45%), Vident Investment Advisory LLC (0.14%) and Morgan Stanley (0.10%). View Institutional Ownership Trends for Cellectis SA.

Who sold Cellectis SA stock? Who is selling Cellectis SA stock?

Cellectis SA's stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Morgan Stanley, Lazard Asset Management LLC and Bank of America Corp DE. View Insider Buying and Selling for Cellectis SA.

Who bought Cellectis SA stock? Who is buying Cellectis SA stock?

Cellectis SA's stock was purchased by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Trexquant Investment LP, Vident Investment Advisory LLC and Eqis Capital Management Inc.. View Insider Buying and Selling for Cellectis SA.

How do I buy Cellectis SA stock?

Shares of Cellectis SA can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Cellectis SA stock cost?

One share of Cellectis SA stock can currently be purchased for approximately $24.25.

Analyst Ratings

Consensus Ratings for Cellectis SA (NASDAQ:CLLS) (?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $44.25 (82.47% upside)

Analysts' Ratings History for Cellectis SA (NASDAQ:CLLS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/10/2017Oppenheimer Holdings Inc.Set Price TargetBuy$40.00LowView Rating Details
4/26/2017Jefferies Group LLCReiterated RatingBuy$47.00LowView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$49.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
2/28/2017Wells Fargo & CoInitiated CoverageOutperform -> OutperformN/AView Rating Details
11/24/2016Piper Jaffray CompaniesSet Price TargetBuy$41.00N/AView Rating Details
4/5/2016Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$45.00N/AView Rating Details
3/1/2016SunTrust Banks, Inc.Initiated CoverageBuy$35.00N/AView Rating Details
7/20/2015Bank of America CorpInitiated CoverageBuy$50.00N/AView Rating Details
(Data available from 5/23/2015 forward)

Earnings

Earnings History for Cellectis SA (NASDAQ:CLLS)
Earnings by Quarter for Cellectis SA (NASDAQ:CLLS)
Earnings History by Quarter for Cellectis SA (NASDAQ:CLLS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/16/2015Q215($0.43)($0.40)$1.23 million$11.10 millionViewN/AView Earnings Details
9/8/2015Q2 2015($0.64)($0.70)$2.37 million$8.85 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cellectis SA (NASDAQ:CLLS)
2017 EPS Consensus Estimate: ($2.76)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.71)($0.65)($0.68)
Q2 20172($0.69)($0.60)($0.65)
Q3 20172($0.73)($0.63)($0.68)
Q4 20172($0.77)($0.73)($0.75)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cellectis SA (NASDAQ:CLLS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Cellectis SA (NASDAQ:CLLS)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Cellectis SA (NASDAQ:CLLS)
Latest Headlines for Cellectis SA (NASDAQ:CLLS)
Source:
DateHeadline
americanbankingnews.com logoQ2 2017 EPS Estimates for Cellectis SA (CLLS) Boosted by Oppenheimer Holdings
www.americanbankingnews.com - May 15 at 7:58 AM
americanbankingnews.com logoCellectis SA (CLLS) Given a $40.00 Price Target at Oppenheimer Holdings Inc.
www.americanbankingnews.com - May 11 at 2:56 PM
finance.yahoo.com logoCellectis Patent Encompassing Broad Uses of Gene Editing Technologies Maintained by USPTO
finance.yahoo.com - May 11 at 2:36 AM
finance.yahoo.com logoCellectis Reports 1st Quarter 2017 Financial Results
finance.yahoo.com - May 9 at 9:20 PM
americanbankingnews.com logo-$0.56 Earnings Per Share Expected for Cellectis SA (CLLS) This Quarter
www.americanbankingnews.com - May 3 at 5:58 PM
americanbankingnews.com logoCellectis SA (CLLS) Getting Somewhat Positive Media Coverage, Study Finds
www.americanbankingnews.com - May 2 at 3:18 PM
americanbankingnews.com logoCellectis SA (CLLS) Given News Impact Rating of 0.16
www.americanbankingnews.com - April 29 at 2:04 PM
americanbankingnews.com logoCellectis SA (CLLS) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 28 at 12:28 PM
americanbankingnews.com logoCellectis SA (CLLS) Given Coverage Optimism Score of 0.29
www.americanbankingnews.com - April 26 at 10:22 PM
americanbankingnews.com logoCellectis SA (CLLS) Given Buy Rating at Jefferies Group LLC
www.americanbankingnews.com - April 26 at 6:46 PM
americanbankingnews.com logoShort Interest in Cellectis SA (CLLS) Drops By 13.3%
www.americanbankingnews.com - April 24 at 5:52 PM
americanbankingnews.com logoCellectis SA (CLLS) Earning Somewhat Critical News Coverage, Analysis Finds
www.americanbankingnews.com - April 23 at 2:57 PM
americanbankingnews.com logoCellectis SA (CLLS) Given Daily Coverage Optimism Rating of 0.08
www.americanbankingnews.com - April 19 at 7:40 AM
americanbankingnews.com logoCellectis SA (CLLS) Getting Favorable Media Coverage, Study Finds
www.americanbankingnews.com - April 16 at 9:06 AM
finance.yahoo.com logoCellectis S.A. to Explore Possible Initial Public Offering of Calyxt, Inc.
finance.yahoo.com - April 12 at 9:22 PM
americanbankingnews.com logoZacks: Analysts Expect Cellectis SA (CLLS) to Announce -$0.56 Earnings Per Share
www.americanbankingnews.com - April 12 at 2:27 PM
americanbankingnews.com logoZacks Investment Research Lowers Cellectis SA (CLLS) to Hold
www.americanbankingnews.com - April 10 at 12:08 PM
americanbankingnews.com logoCellectis SA (CLLS) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - April 3 at 1:35 PM
us.rd.yahoo.com logoCELLECTIS S.A. Financials
us.rd.yahoo.com - March 29 at 4:46 PM
americanbankingnews.com logoOppenheimer Holdings Inc. Reiterates "Buy" Rating for Cellectis SA (CLLS)
www.americanbankingnews.com - March 27 at 10:16 AM
americanbankingnews.com logoCellectis SA (CLLS) Receives Buy Rating from Oppenheimer Holdings Inc.
www.americanbankingnews.com - March 21 at 6:55 PM
uk.finance.yahoo.com logoServier and Pfizer Announce FDA Clearance of IND Application for UCART19 in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia
uk.finance.yahoo.com - March 9 at 3:07 AM
uk.finance.yahoo.com logoFive Additional Leading Physicians to Join Cellectis Clinical Advisory Board
uk.finance.yahoo.com - March 7 at 9:23 PM
uk.finance.yahoo.com logoCellectis Reports 4th Quarter and Full Year 2016 Financial Results
uk.finance.yahoo.com - March 7 at 12:21 PM
us.rd.yahoo.com logoCoverage initiated on Cellectis by Instinet
us.rd.yahoo.com - March 2 at 4:34 PM
finance.yahoo.com logoCoverage initiated on Cellectis by Wells Fargo
finance.yahoo.com - February 28 at 4:34 PM
finance.yahoo.com logoAcorda (ACOR) Reports Narrower-than-Expected Loss in Q4
finance.yahoo.com - February 16 at 10:59 AM
nasdaq.com logoWill Cellectis (CLLS) Continue to Surge Higher? - Nasdaq
www.nasdaq.com - February 10 at 4:37 PM
finance.yahoo.com logoWill Cellectis (CLLS) Continue to Surge Higher?
finance.yahoo.com - February 10 at 4:37 PM
thestreet.com logoCellectis Gains FDA Nod to Test New Gene-Edited Cancer Treatment
us.rd.yahoo.com - February 7 at 5:24 PM
us.rd.yahoo.com logoCellectis Blood Cancer Gets FDA Nod for Trial
us.rd.yahoo.com - February 7 at 5:24 PM
us.rd.yahoo.com logoCellectis SA (ADR) (CLLS) Just Made A Big Step Forward In CAR-T
us.rd.yahoo.com - February 7 at 5:24 PM
uk.finance.yahoo.com logoCellectis to Present at the LEERINK Partners 6th Annual Global Healthcare Conference on Thursday, February 16, 2017 at 1:30 p.m. ET in New York
uk.finance.yahoo.com - February 7 at 5:24 PM
nasdaq.com logoCellectis (CLLS) Shows Strength: Stock Moves 9.1% Higher - Nasdaq
www.nasdaq.com - February 7 at 2:25 AM
uk.finance.yahoo.com logoFDA Grants Cellectis IND Approval to Proceed with the Clinical Development of UCART123, the First Gene Edited Off-the-Shelf CAR T-Cell Product Candidate developed in the U.S.
us.rd.yahoo.com - February 6 at 9:24 PM
finance.yahoo.com logoCellectis: Four Prominent Physicians to Join Cellectis Clinical Advisory Board
finance.yahoo.com - January 23 at 4:36 PM
uk.finance.yahoo.com logoCellectis Studies Safety in New CAR Architecture Controlling CAR T-Cell Functions
us.rd.yahoo.com - January 23 at 5:20 AM
publicnow.com logoCellectis Submits IND Application for UCART123, an Allogeneic Gene Edited CAR T-Cell Product Candidate, in AML and BPDCN
us.rd.yahoo.com - January 3 at 11:07 PM
uk.finance.yahoo.com logoCellectis to Present at the 35th Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2017 at 8:00am PT
uk.finance.yahoo.com - January 3 at 6:05 PM
finance.yahoo.com logoWhy Cellectis (CLLS) Stock Might be a Great Pick
finance.yahoo.com - December 30 at 4:44 PM
finance.yahoo.com logoBlog Coverage Repligen Acquires Maker of Tangential Flow Filtration Cassettes
finance.yahoo.com - December 16 at 4:43 PM
uk.finance.yahoo.com logoCellectis Announces Recombinant DNA Advisory Committee’s (RAC) Unanimous Approval of UCART123 Phase 1 Study Protocols in AML and BPDCN
us.rd.yahoo.com - December 15 at 9:46 PM
us.rd.yahoo.com logo5:04 pm Cellectis announces recombinant DNA Advisory Committee's (:RAC) unanimous approval of UCART123 Phase 1 study protocols in AML and BPDCN
us.rd.yahoo.com - December 15 at 9:46 PM
businesswire.com logoCellectis Reports Financial Results for 3 rd Quarter and First Nine Months 2016 - Business Wire (press release)
www.businesswire.com - November 22 at 9:56 PM
uk.finance.yahoo.com logoCellectis to Participate in Oppenheimer Life Sciences Summit, NY & in Piper Jaffray 28th Annual Health Care Conference, NY
uk.finance.yahoo.com - November 21 at 10:17 PM

Social

Cellectis SA (CLLS) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by MarketBeat.com Staff